Profile data is unavailable for this security.
About the company
Suzhou Zelgen Biopharmaceuticals Co Ltd is a China-based company mainly engaged in pharmaceutical manufacturing. The Company's main products include pharmaceuticals and pharmaceutical intermediates and raw materials. Its products are mainly applied in the fields of tumors, bleeding and blood diseases, immune inflammatory diseases and hepatobiliary diseases. The Company operates in the domestic market and overseas markets.
- Revenue in CNY (TTM)386.57m
- Net income in CNY-260.85m
- Incorporated2009
- Employees867.00
- LocationSuzhou Zelgen Biopharmaceuticals Co LtdNo. 209, Chenfeng Road, Kunshan CitySUZHOU 215300ChinaCHN
- Phone+86 51 257011882
- Fax+86 51 257018306
- Websitehttp://www.zelgen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liaoning Cheng Da Co Ltd | 11.18bn | 17.48m | 14.03bn | 3.36k | 705.38 | 0.4809 | -- | 1.26 | 0.013 | 0.013 | 7.34 | 19.07 | 0.2358 | 4.41 | 6.49 | 3,330,121.00 | -0.5366 | 3.59 | -0.7644 | 5.21 | 16.03 | 14.15 | -2.28 | 9.89 | 0.7792 | -- | 0.2834 | 15.93 | -25.97 | -10.97 | -80.95 | -21.26 | 7.04 | -- |
| Anhui Huaheng Biotechnology Co Ltd | 2.04bn | 454.44m | 14.20bn | 1.69k | 31.27 | 7.42 | -- | 6.96 | 2.88 | 2.88 | 12.94 | 12.15 | 0.6196 | 5.59 | 8.04 | 1,205,674.00 | 13.71 | 16.74 | 21.59 | 22.41 | 38.49 | 39.21 | 22.13 | 22.34 | 0.4552 | 155.98 | 0.4552 | 25.20 | 36.63 | 35.72 | 40.32 | 42.84 | 82.09 | -- |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.43bn | 614.24m | 14.23bn | 2.53k | 23.02 | 4.82 | -- | 4.15 | 1.09 | 1.09 | 6.09 | 5.21 | 0.7246 | 2.04 | 13.84 | 1,356,471.00 | 12.97 | 10.68 | 21.27 | 16.56 | 71.74 | 74.42 | 17.90 | 14.92 | 1.26 | -- | 0.0122 | 72.80 | 10.31 | 10.03 | 22.09 | 18.49 | -16.47 | 39.77 |
| KPC Pharmaceuticals Inc | 7.65bn | 432.35m | 14.60bn | 5.05k | 33.70 | 2.70 | -- | 1.91 | 0.5725 | 0.5725 | 10.15 | 7.15 | 0.8021 | 2.48 | 2.62 | 1,513,702.00 | 4.63 | 5.42 | 7.76 | 9.13 | 43.12 | 43.68 | 5.77 | 5.70 | 1.46 | 53.93 | 0.1688 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 11.78bn | 843.91m | 14.66bn | 11.61k | 17.09 | 1.15 | -- | 1.24 | 0.6394 | 0.6394 | 8.95 | 9.48 | 0.6069 | 3.08 | 6.61 | 1,014,487.00 | 5.75 | 4.85 | 8.50 | 8.17 | 37.09 | 43.00 | 9.48 | 7.03 | 1.82 | -- | 0.1057 | 17.52 | -6.86 | 1.29 | 10.21 | -0.3897 | -2.21 | 0.00 |
| BrightGene Bio-Medical Technology Co Ltd | 1.21bn | 195.77m | 14.75bn | 1.16k | 76.41 | 6.08 | -- | 12.14 | 0.4569 | 0.4569 | 2.87 | 5.75 | 0.2463 | 1.69 | 4.43 | 1,051,700.00 | 3.43 | 6.53 | 4.29 | 7.93 | 54.92 | 56.93 | 13.93 | 19.90 | 1.45 | 4.86 | 0.4787 | 29.31 | 15.94 | 23.68 | -15.51 | 22.56 | 29.13 | -- |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 386.57m | -260.85m | 15.06bn | 867.00 | -- | 9.45 | -- | 38.95 | -1.00 | -1.00 | 1.49 | 6.02 | 0.1621 | 0.2594 | 3.75 | 445,874.00 | -11.74 | -27.13 | -20.82 | -39.20 | 92.29 | 92.75 | -72.40 | -220.71 | 2.15 | -- | 0.3842 | -- | 27.83 | 211.81 | 39.08 | -- | 41.38 | -- |
| Jiang Zhong Pharmaceutical Co Ltd | 4.30bn | 734.24m | 15.97bn | 4.01k | 21.76 | 3.87 | -- | 3.71 | 1.17 | 1.17 | 6.83 | 6.55 | 0.6698 | 4.34 | 13.62 | 1,071,799.00 | 12.35 | 10.82 | 18.82 | 15.08 | 64.01 | 65.02 | 18.44 | 18.17 | 1.47 | -- | 0.0061 | 82.88 | 13.00 | 20.12 | 18.40 | 8.54 | 11.47 | 40.99 |
| Shandong Buchang Pharmaceuticals Co Ltd | 12.37bn | -22.28m | 16.58bn | 8.31k | -- | 1.43 | -- | 1.34 | -0.0202 | -0.0202 | 11.18 | 10.46 | 0.5678 | 1.00 | 9.58 | 1,488,478.00 | -0.9013 | 3.26 | -1.30 | 4.72 | 64.05 | 74.71 | -1.59 | 4.85 | 0.5348 | 2.34 | 0.2522 | 121.01 | -11.41 | -0.6219 | 120.85 | -29.93 | -16.56 | -36.72 |
Data as of Jun 18 2024. Currency figures normalised to Suzhou Zelgen Biopharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
20.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 8.68m | 5.16% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 5.77m | 3.43% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 4.49m | 2.67% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 3.77m | 2.24% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 2.45m | 1.46% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 2.34m | 1.39% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 1.78m | 1.06% |
| Changsheng Fund Management Co., Ltd.as of 31 Dec 2023 | 1.57m | 0.93% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 1.46m | 0.87% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.42m | 0.85% |
More ▼
Data from 31 Dec 2023 - 13 Jun 2024Source: FactSet Research Systems Inc.
